Frank Osterroth

USPTO Granted Patents = 14 (Patent Applications = 4)

CIPO Patents = 6 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 13)

Average Co-Inventor Count = 10.1

ph-index = 4

Forward Citations = 46(Granted Patents)

Company Filing History:

Dana-farber-cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 2014-2018

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10117932 - Uses of immunoconjugates targeting CD138 (2018-11-06),

2. 9995733 - Agents for treating disease (2018-06-12),

3. 9605066 - Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) (2017-03-28),

4. 9550831 - Method for treating psoriasis (2017-01-24),

5. 9540436 - Use of antibodies for detection of IL-10 (2017-01-10),

6. 9512226 - Agent for treating disease (2016-12-06),

7. 9446146 - Methods and agents for improving targeting of CD138 expressing tumor cells (2016-09-20),

8. 9387261 - Immunoconjugates targeting CD138 and uses thereof (2016-07-12),

9. 9334325 - Method for treating psoriasis (2016-05-10),

10. 9289509 - Uses of immunoconjugates targeting CD138 (2016-03-22),

11. 9221914 - Agents targeting CD138 and uses thereof (2015-12-29),

12. 9011864 - Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates (2015-04-21),

13. 8956607 - Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE) (2015-02-17),

14. 8852871 - Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) (2014-10-07),

Title: The Innovative Contributions of Frank Osterroth

Introduction

Frank Osterroth is a notable inventor based in Dietzenbach, Germany. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 14 patents to his name, Osterroth has demonstrated a commitment to advancing medical science and treatment methodologies.

Latest Patents

Osterroth's latest patents include groundbreaking methods for treating diseases associated with target cells expressing CD138. One of his notable inventions involves an immunoconjugate that comprises an engineered targeting antibody aimed at CD138 expressing cells. This method is administered in a multiple dose regimen, which includes at least two doses, ensuring that the aggregate dose administered within an active treatment cycle is either an aggregate maximum tolerable dose (AMTD) or a fraction of it. This innovative approach allows for treatment that exceeds the dose resulting in dose-limiting toxicity (DLT) when administered as a single dose. Additionally, he has developed methods for screening molecules capable of binding to CD4 and activating CD4+CD25+ regulatory T cells, along with antibodies and antibody fragments that facilitate this activation.

Career Highlights

Throughout his career, Frank Osterroth has worked with prominent companies in the biotechnology sector, including Biotest AG and Immunogen, Inc. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in immunotherapy.

Collaborations

Osterroth has collaborated with notable colleagues such as Christoph Bruecher and Christoph Uherek. These partnerships have further enriched his research and development efforts, leading to innovative solutions in the treatment of various diseases.

Conclusion

Frank Osterroth's contributions to the field of immunology through his patents and collaborations highlight his role as a significant inventor. His innovative approaches to treatment methodologies continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.